Cycling MOTS-c and SS-31: User Schedules and the Evidence

Why Users Cycle Mitochondrial Peptides

Most users describe on/off schedules for MOTS-c and SS-31, and the way they approach cycling these peptides is different from how you'd run a cycle of testosterone or even GHRPs. With those, the goal is often to raise a hormone and keep it there.

The usual community argument is that these peptides act as mitohormetic stressors. Think of that term like this: a small, controlled stress on your cellular machinery prompts a positive adaptation. It's the same principle as lifting weights. You don't get stronger by holding a 500-pound barbell all day. You get stronger by lifting it, putting it down, and letting your body adapt and recover. By that logic, constant signaling from a peptide like MOTS-c could blunt the adaptive response, and the 'off' cycle is when your mitochondria consolidate the adaptation. In this view, cycling isn't about classic receptor downregulation; it's about preserving the novelty of the signal.

Treat this as a hypothesis, not a finding. Mitohormesis is a real research concept (set out in a 2010 review, mostly from non-human studies), but no study has tested whether cycling MOTS-c or SS-31 works better than continuous use. The claim that these peptides "don't cause receptor burnout" the way GH secretagogues might is also untested; there's no human data on tolerance to either one. Also, only MOTS-c is a mitochondrial-derived peptide (MDP); SS-31 is a synthetic peptide that targets mitochondria.

What Users Report for MOTS-c

MOTS-c is often called an exercise-mimetic. Your body naturally produces it in response to physical stress: in a 2021 Nature Communications study, exercise raised MOTS-c levels in human skeletal muscle and blood, and MOTS-c injections improved treadmill running in mice of several ages. Users read that as a reason to augment the natural, pulsatile release that happens around training rather than keep levels constantly high. That a pulsed dose mimics an exercise bout is a hypothesis; nobody has measured it in people.

The Endurance Block Cycle

This is the most common approach in community reports. Users run MOTS-c during a specific training block focused on improving work capacity, endurance, or metabolic efficiency, on the theory that its signaling stacks on top of the signaling training already generates. As users describe it:

• Dose: about 5 mg per injection is most common, roughly 10-15 mg per week. Forum doses run from about 1 mg three times weekly to 5-10 mg daily for short blocks.
• Frequency: 2-3 times per week. Some inject 30-90 minutes before hard sessions, a timing no study has tested.
• Duration: usually 4-8 weeks on.
• Off-Cycle: guides range from a few weeks to about two months, with no data behind any length.

Some guides claim the benefits diminish after week 6-7 as the novelty of the signal wears off. We couldn't find a study that measured this.

What the Rodent Schedules Show

In the 2021 study, mice got daily intraperitoneal injections of 5 or 15 mg/kg for about two weeks before treadmill tests, and old mice dosed three times a week (15 mg/kg) from late in life later had better grip strength and gait. Nobody compared that intermittent schedule with daily dosing, so it doesn't show that breaks help, and mouse doses don't convert directly to human doses.

As of October 2026, no peer-reviewed study has given native MOTS-c to people. An analog, CB4211, had one 4-week trial (25 mg daily) and was discontinued. WADA's 2026 Prohibited List names MOTS-c under S4.4.1, banned at all times and not a Specified Substance (see legal and ethical considerations for athletes).

What Users Report for SS-31

SS-31 (also known as elamipretide) is a different beast. It's not an exercise-mimetic like MOTS-c. It selectively binds cardiolipin, a key phospholipid in the inner mitochondrial membrane that gets damaged by oxidative stress. In cell and animal studies, protecting cardiolipin helps maintain the integrity of the electron transport chain while reducing reactive oxygen species (ROS).

Users tend to reach for it when the body is under heavy stress: contest prep, a brutal strength block, or coming back from an injury. In that community framing, it's a firefighter, not a construction worker, so the cycle follows the length of the stressor rather than a training pulse. No trial has tested SS-31 in healthy athletes. As users describe it:

• Dose: about 0.5-4 mg per day by subcutaneous injection, with one widely shared protocol reaching 10 mg per day.
• Frequency: once daily, often in the morning. No study has tested timing.
• Duration: about 4 weeks, with some running up to 8 weeks before stopping.

Some guides argue that long use could blunt the body's own endogenous antioxidant responses. That hasn't been studied for SS-31.

How the Trials and the Label Dose It

As of October 2026, elamipretide is a prescription medicine. The FDA granted it accelerated approval as Forzinity on September 19, 2025, for Barth syndrome in patients weighing at least 30 kg. The label dose is 40 mg subcutaneously once daily, with no off periods; 8 of the 12 Barth patients stayed on daily dosing for 168 weeks in the open-label extension. Approval rests on knee-extensor strength after the trial missed its primary endpoints.

MMPOWER-3 also dosed continuously: 40 mg a day for 24 weeks in 218 adults with primary mitochondrial myopathy, and it missed both primary endpoints (walking distance and fatigue). So the human data comes from uninterrupted use at roughly 4 to 80 times the doses users describe, and none of it tested cycling. Research-use vials sold online aren't equivalent to the prescription product.

Here's how they compare side-by-side:

Stacking and Phasing

Many users run both. Forum threads often describe SS-31 first, then MOTS-c; other guides phase them within a larger training macrocycle, such as this 16-week layout:

1. Weeks 1-6 (Accumulation/High-Volume Phase): a MOTS-c cycle, 2-3x per week before the hardest sessions, intended to improve work capacity and nutrient partitioning.
2. Weeks 7-8 (Intensification/Peak Phase): off all mitochondrial peptides, riding the adaptations from the MOTS-c cycle while pushing peak strength or performance.
3. Weeks 9-10 (Deload/Recovery Phase): a short SS-31 cycle, used daily after 8 weeks of hard training, meant to support mitochondrial repair and prime the system for the next block.
4. Weeks 11-16 (Off-Cycle/Baseline): completely off, to let the system normalize, on the idea that this allows your mitochondria to fully reset their sensitivity.

This is a theoretical layout, not a tested one. No study has given MOTS-c and SS-31 together or in sequence, and nobody has measured how fast mitochondria "reset." Fitting these peptides into a cutting phase is covered in cycling mitochondrial peptides for fat loss, and the performance evidence in endurance applications.

What We Still Don't Know

The biggest gap is whether either peptide loses effect with steady use in people; cycling is built on that untested assumption. MOTS-c doesn't even have a human dose to start from. For SS-31, the open question is whether the low doses users report do anything measurable, since every trial used 40 mg or more a day, and the confirmatory Barth trial won't test on/off schedules. Long-term safety is covered in long-term health implications of mitochondrial peptides.